T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients

J Cereb Blood Flow Metab. 2011 Oct;31(10):2054-64. doi: 10.1038/jcbfm.2011.39. Epub 2011 Apr 20.


A 'vascular normalization index' (VNI) based on the changes in the magnetic resonance imaging (MRI) parameters K(trans) and cerebral blood volume (CBV), combined with blood sampling, has been shown to correlate with patient outcome in recurrent glioblastoma after a single dose of antiangiogenic therapy. Here, by applying a novel contrast agent extravasation correction method insensitive to variations in tissue mean transit time, we show that a similar VNI parameter can be derived from a single dynamic susceptibility contrast MR acquisition rather than the three parameters shown previously. Our results show that this new VNI parameter, which combines changes in tumoral CBV and an apparent transfer constant from our leakage correction method, may provide prognostic information in an even simpler manner than prior efforts.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Brain Neoplasms* / diagnostic imaging
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / mortality
  • Brain Neoplasms* / physiopathology
  • Contrast Media / administration & dosage
  • Disease-Free Survival
  • Female
  • Glioblastoma* / diagnostic imaging
  • Glioblastoma* / drug therapy
  • Glioblastoma* / mortality
  • Glioblastoma* / physiopathology
  • Humans
  • Magnetic Resonance Angiography / methods*
  • Male
  • Quinazolines / administration & dosage*
  • Radiography
  • Survival Rate


  • Angiogenesis Inhibitors
  • Contrast Media
  • Quinazolines
  • cediranib